Physician No program year No payments reported Source: CMS Open Payments, 2026 publication

James Moretti

Family Medicine Pittsburgh, PA

NPI 1063597177 CMS profile 1219258

2589 Washington Road, Suite 423, Pittsburgh, PA 15241

Open in the dashboard

General payments

$0

None reported

Research payments

$0

Paid to them · None reported

Ownership & investment interest

$0

None reported

The CMS Open Payments record contains no reported payments to James Moretti of Pittsburgh, PA.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

2,483

Median for Family Practice: 1,826

Drug cost

$193,582

Median for Family Practice: $120,094

Branded share of claims

14.1%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 43 $38,089
Eliquis Apixaban Brand 20 $28,397
Mounjaro Tirzepatide Brand 21 $27,965
Ozempic Semaglutide Brand 20 $18,744
Xarelto Rivaroxaban Brand 19 $16,554
Rybelsus Semaglutide Brand 18 $16,398
Repatha Syringe Evolocumab Brand 12 $9,165
Invokana Canagliflozin Brand 13 $7,386
Breo Ellipta Fluticasone/Vilanterol Brand 14 $5,428
Rosuvastatin Calcium Generic 247 $3,231

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$14,603

Medicare's payments for the services billed

Medicare patients

65

Average age 73

Services billed

142

38 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 51%
Diabetes 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Other Family Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record